
靶点 RNA-seq 脂质代谢 阿尔茨海默病 senaparib 艾玛昔替尼 埃万妥单抗
#今日行业热点#①Nature:From target discovery to clinical drug development with human genetics
综述:从靶点发现到人类遗传学临床药物开发
(资料图片)
DOI: 10.1038/s41586-023-06388-8
②Nature Communications:FAP106 is an interaction hub for assembling microtubule inner proteins at the cilium inner junction
FAP106是纤毛内部连接组装微管内部蛋白(MIPs)的相互作用枢纽
DOI: 10.1038/s41467-023-40230-z
③Nature Communications:Coordinated single-cell tumor microenvironment dynamics reinforce pancreatic cancer subtype
通过单细胞RNA-seq的肿瘤微环境(TME)进行表征揭示与胰腺导管腺癌(PDAC)表型相关的细胞类型和相互作用
DOI: 10.1038/s41467-023-40895-6
④Nature Communications:Neuronal ER-plasma membrane junctions couple excitation to Ca2+-activated PKA signaling
神经元内质网(ER)和质膜(PM)连接激活细胞内Ca2+驱动的非受体形式的蛋白激酶A (PKA)信号
DOI: 10.1038/s41467-023-40930-6
⑤Nature Communications:Hepatic SREBP signaling requires SPRING to govern systemic lipid metabolism in mice and humans
SPRING是小鼠和人类肝脏SREBP信号通路和全身脂质代谢的核心组成部分
DOI: 10.1038/s41467-023-40943-1
⑥Nature Neuroscience:Efficacy and Safety of Dupilumab in Older Patients (Aged 80 Years and Above) with Atopic Dermatitis: A Prospective Study
浸润的CD8+T细胞在3D人类神经免疫轴模型中加剧阿尔茨海默病(AD)的病理机制
DOI: 10.1038/s41593-023-01415-3
⑦聚腺苷二磷酸核糖聚合酶(PARP)抑制剂senaparib的新药上市申请获CDE受理,用于III-IV期上皮性卵巢癌、输卵管癌或原发性腹膜癌
⑧JAK1抑制剂艾玛昔替尼片(SHR0302)新适应症的上市申请获CDE受理,推测申报适应症为活动性强直性脊柱炎(AS)
⑨EGFR/c-Met双抗药物埃万妥单抗(Rybrevant)的补充上市申请获FDA受理,联合化疗用于EGFR外显子20插入突变、局部晚期或转移性非小细胞肺癌
⑩PCSK9大环肽抑制剂MK-0616用于高胆固醇血症的Ⅲ期临床CORALreef首批受试者入组
科学探索的世界充满挑战,AtaGenix致敬每一位拓荒者,更致力于成为您信赖的合作伙伴!